Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IS30XX
- Development stage
- Preclinical
- Lead developer
- iSeek Biopharma
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IS30XX is a discovery-stage radiopharmaceutical diagnostic PET imaging agent being developed by iSeek Biopharma for applications in hematological oncology. As a PET (positron emission tomography) tracer, it is intended to provide high-sensitivity imaging of specific biological targets associated with blood cancers, aiding in diagnosis, staging, and treatment monitoring. While iSeek Biopharma's core technology platform is centered on targeting the LFA-1 (leukocyte functional antigen-1) receptor, the specific molecular target for IS30XX has not been explicitly disclosed in current pipeline materials.
Beyond the preview
Go deeper on IS30XX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IS30XX.